Clone-specific markers used for the screening included PML/RARalpha, AML1/ETO and CBFbeta/MYH11 fusion genes, chimeric products with the MLL gene and for the first time also the FLT3/ITD in patients with AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.